Neuromelanin Containing Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuromelanin (NM)-containing neurons are pigmented neurons primarily found in the substantia nigra pars compacta (SNc) and locus coeruleus (LC) that are selectively vulnerable in Parkinson's disease.[1]
Neuromelanin is a dark polymer pigment synthesized from oxidized dopamine (in SNc) or norepinephrine (in LC). It accumulates in neurons throughout life, reaching high concentrations in older individuals.[1] NM-containing neurons are:
- Located primarily in: Substantia nigra pars compacta (SNc), Locus coeruleus (LC)
- Estimated numbers: ~500,000 NM neurons in human SNc[2]
- Pigment type: Eumelanin/pheomelanin copolymer[1]
- Iron chelation: NM binds iron, potentially reducing oxidative stress[1]
- Free radical scavenging: Neutralizes reactive oxygen species[1]
- Detoxification: Sequesters toxic metals (mercury, cadmium)[1]
- Autophagy regulation: NM may influence cellular waste removal[1]
- Modulates dopamine/norepinephrine neurotransmission[1]
- May act as a UV light absorber[1]
- Involved in synaptic function[1]
-
Oxidative Stress
- High iron in SNc + NM = Fenton reaction (OH• production)[3]
- Mitochondrial complex I deficiency[3]
- Reduced glutathione levels[3]
-
Alpha-Synuclein Aggregation
- NM may catalyze alpha-synuclein fibril formation[4]
- Lewy bodies contain NM granules[4]
- NM-synuclein complexes are toxic[4]
-
Calcium Dysregulation
- Pacemaker activity increases metabolic demand[5]
- Mitochondrial overload[5]
- Cellular exhaustion[5]
-
Neuroinflammation
- Microglial activation near NM neurons[6]
- Cytokine release damages neurons[6]
- Loss of NM neurons is a hallmark of PD[1]
- NM loss correlates with disease duration[1]
- NM imaging as a biomarker[7]
- Incidental Lewy Body Disease
- Progressive Supranuclear Palsy
- Multiple System Atrophy
- Iron chelators: Deferoxamine, clioquinol[8]
- Antioxidants: CoQ10, vitamin E[8]
- Calcium channel blockers: Isradipine (in trials)[5]
- NM as drug delivery vehicle[1]
- Melanin-based antioxidants[1]
The study of Neuromelanin Containing Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Zecca L, et al. (2004). Neuromelanin: the black pigment of black substance. Progress in Neurobiology, 74(2), 115-127. https://doi.org/10.1016/j.pneurobio.2004.08.002
- Hirsch E, et al. (1988). Melanized dopaminergic neurons are more vulnerable to MPTP neurotoxicity. Journal of Neurochemistry, 51(6), 1903-1912.
- Zecca L, et al. (2004). Iron, brain ageing and neurodegenerative disorders. Nature Reviews Neuroscience, 5(11), 863-873. https://doi.org/10.1038/nrn1450
- Sulzer D, et al. (2000). Neuromelanin is a radical sink. Neuron, 28(1), 293-295. https://doi.org/10.1016/S0896-6273(00)00149-0
- Guzman JN, et al. (2010). Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature, 468(7324), 696-700. https://doi.org/10.1038/nature09536
- McGeer PL, et al. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38(8), 1285-1291.
- Zucca FA, et al. (2017). Neuromelanin in aging and disease. Anatomical Record, 300(8), 1538-1552. https://doi.org/10.1002/ar.23579
- Dexter DT, et al. (1991). Increased iron in the substantia nigra compared to normal aging brains: implications for neurodegeneration. Journal of Neural Transmission, 83(1-2), 67-70.